A randomized, open-label trial of ramelteon to prevent postoperative delirium in patients undergoing coronary artery bypass grafting

A randomized, open-label trial of ramelteon to prevent postoperative delirium in patients undergoing coronary artery bypass grafting - Trial of ramelteon to prevent postoperative delirium in patients undergoing coronary artery bypass grafting

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006341

Enrollment

Registered

2011-09-13

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery bypass grafting

Interventions

intervention group ramelteon 8mg continuous administration for three days after operation non intervention group drug free

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: none

Exclusion criteria

Exclusion criteria: hepatic impairment taking fluvoxamine maleate

Design outcomes

Primary

Measure	Time frame
incidence rate of postoperative delirium	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026